Voya Investment Management LLC Y M Abs Therapeutics, Inc. Transaction History

Voya Investment Management LLC

  • $78.9 Billion
  • Q4 2024

A detailed history of Voya Investment Management LLC transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 11,695 shares of YMAB stock, worth $66,895. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,695
Previous 12,433 5.94%
Holding current value
$66,895
Previous $163,000 44.17%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
SELL
$7.76 - $15.69 $5,726 - $11,579
-738 Reduced 5.94%
11,695 $91,000
Q3 2024

Feb 07, 2025
SELL
$9.95 - $15.39 $1,671 - $2,585
-168 Reduced 1.33%
12,433 $163,000
Q3 2024

Nov 14, 2024
SELL
$9.95 - $15.39 $1,671 - $2,585
-168 Reduced 1.33%
12,433 $163,000
Q2 2024

Feb 07, 2025
BUY
$11.6 - $17.25 $719 - $1,069
62 Added 0.49%
12,601 $152,000
Q2 2024

Dec 03, 2024
BUY
$11.6 - $17.25 $1,948 - $2,898
168 Added 1.35%
12,601 $152,000
Q2 2024

Aug 14, 2024
BUY
$11.6 - $17.25 $719 - $1,069
62 Added 0.49%
12,601 $152,000
Q1 2024

Feb 07, 2025
BUY
$6.57 - $18.69 $696 - $1,981
106 Added 0.85%
12,539 $203,000
Q1 2024

Dec 06, 2024
BUY
$6.57 - $18.69 $696 - $1,981
106 Added 0.85%
12,539 $203,000
Q1 2024

May 15, 2024
SELL
$6.57 - $18.69 $20,143 - $57,303
-3,066 Reduced 19.65%
12,539 $203,000
Q4 2023

Feb 07, 2025
SELL
$4.88 - $7.42 $111,093 - $168,916
-22,765 Reduced 59.33%
15,605 $106,000
Q4 2023

Feb 14, 2024
SELL
$4.88 - $7.42 $111,093 - $168,916
-22,765 Reduced 59.33%
15,605 $106,000
Q3 2023

Feb 07, 2025
BUY
$4.86 - $7.23 $19,556 - $29,093
4,024 Added 11.72%
38,370 $209,000
Q3 2023

Nov 14, 2023
BUY
$4.86 - $7.23 $19,556 - $29,093
4,024 Added 11.72%
38,370 $209,000
Q2 2023

Feb 07, 2025
SELL
$5.68 - $10.34 $61,872 - $112,633
-10,893 Reduced 24.08%
34,346 $233,000
Q2 2023

Aug 14, 2023
SELL
$5.68 - $10.34 $61,872 - $112,633
-10,893 Reduced 24.08%
34,346 $233,000
Q1 2023

Feb 07, 2025
BUY
$2.83 - $5.11 $92,840 - $167,638
32,806 Added 263.86%
45,239 $226,000
Q1 2023

May 15, 2023
BUY
$2.83 - $5.11 $21,491 - $38,805
7,594 Added 20.17%
45,239 $226,000
Q4 2022

Feb 07, 2025
BUY
$3.0 - $15.17 $27,579 - $139,457
9,193 Added 32.31%
37,645 $183,000
Q4 2022

Feb 14, 2023
BUY
$3.0 - $15.17 $27,579 - $139,457
9,193 Added 32.31%
37,645 $183,000
Q3 2022

Feb 07, 2025
BUY
$13.96 - $19.67 $223,625 - $315,093
16,019 Added 128.84%
28,452 $410,000
Q3 2022

Mar 03, 2023
SELL
$13.96 - $19.67 $128,334 - $180,826
-9,193 Reduced 24.42%
28,452 $410,000
Q2 2022

Aug 15, 2022
BUY
$8.22 - $15.13 $5,071 - $9,335
617 Added 2.22%
28,452 $430,000
Q1 2022

May 16, 2022
BUY
$6.55 - $17.42 $92,839 - $246,911
14,174 Added 103.76%
27,835 $331,000
Q4 2021

Feb 14, 2022
SELL
$15.51 - $29.31 $635 - $1,201
-41 Reduced 0.3%
13,661 $221,000
Q2 2021

Aug 16, 2021
SELL
$25.45 - $37.64 $104,166 - $154,060
-4,093 Reduced 23.0%
13,702 $463,000
Q1 2021

May 17, 2021
BUY
$29.16 - $51.96 $45,839 - $81,681
1,572 Added 9.69%
17,795 $538,000
Q4 2020

Feb 16, 2021
BUY
$37.86 - $54.26 $105,212 - $150,788
2,779 Added 20.67%
16,223 $803,000
Q3 2020

Nov 16, 2020
BUY
$35.13 - $43.62 $106,373 - $132,081
3,028 Added 29.07%
13,444 $516,000
Q2 2020

Aug 14, 2020
SELL
$23.66 - $49.53 $32,366 - $67,757
-1,368 Reduced 11.61%
10,416 $450,000
Q1 2020

May 15, 2020
BUY
$14.39 - $35.8 $8,087 - $20,119
562 Added 5.01%
11,784 $308,000
Q4 2019

Feb 14, 2020
BUY
$23.81 - $33.78 $267,195 - $379,079
11,222 New
11,222 $351,000

Others Institutions Holding YMAB

# of Institutions
113
Shares Held
26.9M
Call Options Held
5.6K
Put Options Held
900
View Full List

About Y-mAbs Therapeutics, Inc.

YMAB Quotes by TradingView
  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $250M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email